Company profile: Kaleido
1.1 - Company Overview
Company description
- Provider of wearable insulin pump solutions for diabetes management, including the Kaleido insulin pump delivering continuous fast-acting insulin over 24 hours with hourly adjustments, connecting via a tube and infusion set and wearable up to three days; the Kaleido with Diabeloopβs DBLG1 Hybrid Closed Loop using Dexcom G6 and a handheld device to auto-adjust dosing; and a starter kit with two reusable pumps, a handset, training and support.
Products and services
- Kaleido with Diabeloopβs DBLG1 Hybrid Closed Loop: A hybrid closed-loop system combining the Kaleido pump, Dexcom G6 CGM, and a handheld device to automatically adjust insulin dosing from real-time data for optimized diabetes management
- Kaleido Insulin Pump: A programmable insulin pump delivering continuous fast-acting insulin over 24 hours, adjustable in hourly blocks, connected via tube and infusion set, wearable up to three days
- Kaleido Starter Kit: A turnkey kit supplying two reusable pumps, a handset, plus training and support, designed for ease of use and to support a flexible lifestyle with the Kaleido pump system
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Kaleido
Adocia
HQ: France
Website
- Description: Provider of biotechnology therapies specializing in tissue regeneration and diabetes treatments, developing medicines with already-approved therapeutic proteins. Offerings include BioChaperone Lispro ultra-rapid insulin, BioChaperone Combo glargine+lispro, AdoShell Islets hydrogel implant, M1Pram and BioChaperone LisPram co-formulations, and AdOral Sema oral semaglutide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Adocia company profile β
Vitae Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies, building a portfolio of novel, best-in-class small molecules and biologics addressing significant unmet needs, including chronic kidney disease, diabetes, atherosclerosis, and Alzheimerβs. Programs span immunology, oncology, neuroscience, eye care, aesthetics, and patient access and support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Vitae Pharmaceuticals company profile β
Perceive Bio
HQ: United States
Website
- Description: Provider of novel ophthalmology technologies and therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Perceive Bio company profile β
Sensulin
HQ: United States
Website
- Description: Provider of diabetes drug discovery focused on a once-a-day glucose-responsive insulin for type 1 and type 2 diabetes, designed to reduce hypoglycemia risk and long-term complications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Sensulin company profile β
Rubin Medical
HQ: Sweden
Website
- Description: Provider of diabetes aids for the public and healthcare sectors as a pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Rubin Medical company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Kaleido
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kaleido
2.2 - Growth funds investing in similar companies to Kaleido
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Kaleido
4.2 - Public trading comparable groups for Kaleido
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β